# The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors

> **NCT07109167** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Second Affiliated Hospital of Shandong First Medical University** · enrollment: 30 (estimated)

## Conditions studied

- Biliary Tract Neoplasms

## Interventions

- **DRUG:** Benmelstobart combined with gemcitabine and cisplatin

## Key facts

- **NCT ID:** NCT07109167
- **Lead sponsor:** The Second Affiliated Hospital of Shandong First Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2026-08-01
- **Final completion:** 2027-08-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07109167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07109167, "The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07109167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*